Intriguingly, several clinical trials have reported the pleiotropic beneficial effects of SGLT-2 inhibition on vascular function [14, 15], with the underlying mechanism postulated to be due, in part, to indirect effects mediated by improved diabetes status, such as weight loss, improved glycemic control, diuresis-induced blood volume reduction, as well as potential direct effects on the vasculature, such as improvements in endothelial function and vascular stiffness [16–18]. The gene discussed is SLC5A2; the disease is diabetes mellitus.